Netherlands· NL-b1e4967cbfb0
Herceptin 600 mg/5 ml, oplossing voor injectie
A medicinal product containing trastuzumab, registered in Netherlands by Roche Registration GmbH.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- TRASTUZUMAB
- Manufacturer
- Roche Registration GmbH
- Country
- Netherlands (NL)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/00/145
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Trastuzumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SwitzerlandHerceptin subkutan
- United KingdomHerceptin 150mg powder for concentrate for solution for infusion vialsRoche Products Ltd
- FinlandDazublysCuraTeQ Biologics (Malta) Limited
- CzechiaDAZUBLYSCuraTeQ Biologics (Malta) Limited, Floriana
- BelgiumDazublys 150 mgCuraTeQ Biologics (Malta)
- SwedenDazublys 150 mg Pulver till koncentrat till infusionsvätska, lösningCuraTeQ Biologics (Malta) Limited
- PolandDazublysCuraTeQ Biologics s.r.o.
- IcelandDazublysCuraTeQ Biologics (Malta) Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Dazublys, Herceptin
- Liechtenstein · Dazublys, Herceptin
- Norway · Dazublys, Herceptin
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/018f2a20-75dd-49a4-9ad9-5e9e394dafbc GET /v1/drugs/018f2a20-75dd-49a4-9ad9-5e9e394dafbc?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_nl.pdf",
"strength": null,
"atc_label": null,
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp111703",
"excipients": [
"HISTIDINE, (L-)",
"HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
"HYALURONIDASE PH20, HUMAAN, RECOMBINANT",
"METHIONINE, (L-)",
"POLYSORBAAT 20 (E 432)",
"TREHALOSE (Alpha, Alpha-) 2-WATER",
"WATER VOOR INJECTIE"
],
"substances": [
"TRASTUZUMAB"
],
"leaflet_url": null,
"authorised_at": "2013/08/26",
"procedure_number": "EMEA/H/C/000278",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/00/145",
"additional_monitoring": "N"
}See everything about trastuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.